- Email: [email protected]
PMH27 COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING
Paris Abstracts PMH25 CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY Hong J1, Reed C2, Novick D2, Haro JM3, Aguado J3 1 London School of Economics, London, UK, 2Eli Lilly and Company, Windlesham, Surrey, UK, 3Sant Joan de Deu-SSM, Barcelona, Spain OBJECTIVES: To investigate the consequences of medication non-adherence on relapse, recurrence, remission and recovery, and to estimate costs associated with non-adherence over 21-months in the treatment of bipolar disorder following a manic or mixed episode. METHODS: EMBLEM is a prospective, observational study on patient outcomes with a manic/mixed episode. Data was collected at baseline, during the first 12 weeks of treatment (acute phase), at 6 month post-baseline and at 6-month intervals up to 24 months (maintenance phase). Medication adherence was assessed at each visit by investigators as: i) not prescribed medication; ii) almost always adheres; iii) adheres half of the time; and iv) never adheres to medication. Adherence was defined as always answering ‘always adheres’ and non-adherence was defined when one or more response of ‘adheres half of the time’ or ‘never adheres’. In this post-hoc analysis, Cox proportional hazards models with non-adherence, adjusted for patient characteristics, investigated its impact on clinical outcomes. Multivariate analyses were performed to estimate the cost of resource use associated with non-adherence during the maintenance phase, using a log-link function. UK unit costs were applied to resource use. RESULTS: Of the 1341 patients analysed, 23.6% were non-adherent over 21-months. Non-adherence was significantly associated with a higher risk of relapse (HR:2.40, 95%CI:2.04–2.83) and recurrence (HR:1.72, 95%CI:1.27–2.33) as well as lower remission rates (Hazard ratio (HR):0.71, 95%CI:0.59–0.86) and recovery (HR:0.65, 95%CI:0.51–0.81). In addition, costs incurred by non-adherent patients during this period were significantly higher than those of adherent patients (£10231 vs. £7379). This disparity resulted mainly from differences in in-patient costs (£4796 vs. £2150). CONCLUSIONS: Non-adherence in bipolar patients after a manic/mixed episode is associated with higher than twice the risk of relapse of adherent patients which has economic implications for health care providers. A study limitation is that adherence was assessed by investigators using a single-item measure. PMH26 A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE Ye X1, Roberts CS2, Hoffman DL3, Liu F1, Iorga SR4 1 i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA, 2Pfizer Inc, New York, NY, USA, 3 Pfizer, Inc, New London, CT, USA, 4i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA OBJECTIVES: To compare treatment patterns and health care costs among subjects newly treated with donepezil versus subjects newly treated with rivastigmine or galantamine. METHODS: This retrospective claims-based analysis utilized data from a large US managed care plan. Subjects were q50 years of age; filled q1 prescription for donepezil, rivastigmine, or galantamine from January 1, 2005–December 31, 2007; and were continuously enrolled for q18 months. Rivastigmine and galantamine cohorts were each matched to donepezil cohort at 1:3 ratio by propensity score. Logistic regression, Cox regression, and generalized linear models with gamma distribution and log link were used to examine adherence (medication possession ratio q80%), persistence/discontinuation and total health care costs, as appropriate. RESULTS: Of 488 rivastigmine subjects, 33.0% were adherent and 69.3% discontinued medication while the rates of adherence and discontinuation in the matched 1,464 donepezil users were 42.4% and 60.7%, respectively. Compared with rivastigmine cohort, donepezil subjects were more likely to be adherent (OR: 1.395, 95% CI: 1.117–1.742, p 0.003) and had a lower risk of discontinuation (RR: 0.827, 95% CI: 0.729–0.939, p 0.003). Mean annualized total health care costs did not differ significantly between two cohorts (donepezil: $11,431; rivastigmine: $12,358), although donepezil appeared to be associated with lower costs in regression analysis (Cost Ratio: 0.898, 95% CI: 0.803–1.005, p 0.06). Of 597 galantamine subjects, 36.5% were adherent and 65.7% discontinued medication while the rates of adherence and discontinuation in the matched 1,791 donepezil users were 42.0% and 60.6%, respectively. Donepezil users were more likely to be adherent than galantamine users (OR: 1.261, 95% CI: 1.038–1.534, p 0.020); however, discontinuation risk was similar. Annualized health care costs were similar in the two cohorts both bivariately (donepezil: $11,644; galantamine:$ 10,876) and in regression analysis. CONCLUSIONS: Donepezil users demonstrated better adherence than each of the matched cohorts, and lower discontinuation risk than the rivastigmine cohort. Total costs were similar.
A355 PMH27 COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING Navarro Espigares JL1, Carnero Pardo C1, Hernández Torres E1, Espejo Martinez B1, Espinosa Garcia M2, Saez Zea CR1, Lopez Alcalde S3, Vilchez Carrillo RM1 1 University Hospital Virgen de las Nieves, Granada, Spain, 2FIDYAN Neurocenter, Granada, Spain, 3University Hospital Virgen de las Nieves, Granada, SC, Spain OBJECTIVES: Cost analysis of different dementia screening tests available in Spain from the health care system perspective. METHODS: A number of screening tests for General Practitioner (GP) consultation have been compared. According to their duration they were classified in long ( 5 minutes) and short ( 5 minutes) tests. The long tools evaluated were Mini-Mental State Examination (MMSE), a Spanish validated adaptation of MMSE (MEC-30), Eurotest and Memory Alteration Test (T@M). On the other hand, short tools evaluated were Fototest, Semantic Verbal Fluency (SVF), Memory Impairment Screen (MIS), Clock test (CT) and Short Portable Mental Status Questionnaire (SPMSQ) or Pfeiffer Test. Direct costs of the screening and the costs of verification at hospital of the preliminary diagnosis were calculated. Costs by correct diagnosis (TP) have been calculated based on public prices of GP’s consultations and on analytical accounting of the public University Hospital Hospital Virgen de las Nieves (Granada, Spain). RESULTS: Total cost of each screening test was calculated as the addition of the GP study for each patient (long screening a64.4a and short screening a43.5) plus the cost of the specific study for confirmation at hospital for positive diagnosis (laboratory tests a123.61 and medical consultations a208.86 per patient). Lower cost tests are Fototest (a527 per TP) and SPMSQ (a545.2 per TP). The rest of evaluated tests have higher costs (10–20%: CT, FVS, MEC-30 and Eurotest; 20–30%: MIS and T@M; 60%: MMSE). CONCLUSIONS: The MMSE, the most used screening test, is the most expensive. Fototest and SPMSQ are the screening test of lowest cost. Both tests are short, applicable to illiterates and show the same effectiveness as long tools. According to previous results, it may be recommendable to take into account the differences among tests in terms of opportunity costs and potential budgetary impact, in the design of a broad regional screening dementia strategy. PMH28 INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER Liu X1, Gelwicks SC2, Faries D2, Watson PR1, Johnstone BM1 1 Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA OBJECTIVES: Our recent study showed that multiple factors including patient characteristics, comorbidities, prior medications, prior health care utilization and costs were associated with initial prescription dosage of duloxetine in the treatment of major depressive disorder (MDD). The purpose of the present study was to examine the associations between initial prescription dosage of duloxetine and hospitalization and costs in the 1-year follow-up period. METHODS: Of 10,128 patients with MDD in a large commercial administrative claims database who were initiated on duloxetine between July 1, 2005 and June 30, 2006 and had no prescriptions of duloxetine in the prior 6 months, 6132 (60.5%) had continuous enrollment for 12 months prior to and post-duloxetine initiation. According to initial prescription dose, patients were divided into 3 cohorts: low-dose ( 60 mg/day, n 1,989), mid-dose (60 mg/day, n 3,733), and high-dose ( 60 mg/day, n 410). Intent-to-treat analysis was conducted to compare health care utilization and costs in the 1 year prior and post-initiation across the 3 cohorts. RESULTS: During the post 1 year, hospitalization rate was significantly reduced by 5.7% for mid-dose cohort (p 0.001), 6.9% for high-dose cohort (p 0.05), and 7.3% for low-dose cohort (p 0.001). Pharmacy costs in the post 1 year increased in all 3 cohorts: low-dose, $672 (p 0.001); mid-dose, $825 (p 0.001); and high-dose, $1437 (p 0.05). However, mean medical costs declined in high-dose patients ($2617) and mid-dose patients ($340), but increased in low-dose patients ($261). Mean total health care costs numerically declined by $1,180 ($20,225-$21,406) in high-dose patients, but increased in low-dose patients by $933 ($18,002–$17,069) and mid-dose patients by $485 ($16,917-$16,432), although these cost changes were not significant. CONCLUSIONS: The hospitalization rate was significantly reduced in all patients after duloxetine initiation. Although pharmacy costs increased more in high-dose patients than in mid- and low-dose patients; the higher medication costs were offset by lower medical costs. PMH29 DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF DULOXETINE VERSUS OTHER ANTIDEPRESSANTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK Shi L1, Liu J1, Zhao Y2 1 Tulane University, New Orleans, LA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: This retrospective study aimed to compare health care utilization associated with duloxetine versus other antidepressants for patients with major depressive disorder (MDD) in the Veterans Affairs (VA) health system. Duloxetine was not on the VA national drug formulary. METHODS: The electronic medical records from October 2004 to October 2008 were extracted from the VA Veterans Integrated Service Network 16 data warehouse. All patients were treated with either duloxetine monotherapy or other antidepressants (non-duloxetine) over the study period. The first dispense date of the index agent was defined as the index date. All patients
A355 PMH27 COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING Navarro Espigares JL1, Carnero Pardo C1, Hernández Torres E1, Espejo Martinez B1, Espinosa Garcia M2, Saez Zea CR1, Lopez Alcalde S3, Vilchez Carrillo RM1 1 University Hospital Virgen de las Nieves, Granada, Spain, 2FIDYAN Neurocenter, Granada, Spain, 3University Hospital Virgen de las Nieves, Granada, SC, Spain OBJECTIVES: Cost analysis of different dementia screening tests available in Spain from the health care system perspective. METHODS: A number of screening tests for General Practitioner (GP) consultation have been compared. According to their duration they were classified in long ( 5 minutes) and short ( 5 minutes) tests. The long tools evaluated were Mini-Mental State Examination (MMSE), a Spanish validated adaptation of MMSE (MEC-30), Eurotest and Memory Alteration Test (T@M). On the other hand, short tools evaluated were Fototest, Semantic Verbal Fluency (SVF), Memory Impairment Screen (MIS), Clock test (CT) and Short Portable Mental Status Questionnaire (SPMSQ) or Pfeiffer Test. Direct costs of the screening and the costs of verification at hospital of the preliminary diagnosis were calculated. Costs by correct diagnosis (TP) have been calculated based on public prices of GP’s consultations and on analytical accounting of the public University Hospital Hospital Virgen de las Nieves (Granada, Spain). RESULTS: Total cost of each screening test was calculated as the addition of the GP study for each patient (long screening a64.4a and short screening a43.5) plus the cost of the specific study for confirmation at hospital for positive diagnosis (laboratory tests a123.61 and medical consultations a208.86 per patient). Lower cost tests are Fototest (a527 per TP) and SPMSQ (a545.2 per TP). The rest of evaluated tests have higher costs (10–20%: CT, FVS, MEC-30 and Eurotest; 20–30%: MIS and T@M; 60%: MMSE). CONCLUSIONS: The MMSE, the most used screening test, is the most expensive. Fototest and SPMSQ are the screening test of lowest cost. Both tests are short, applicable to illiterates and show the same effectiveness as long tools. According to previous results, it may be recommendable to take into account the differences among tests in terms of opportunity costs and potential budgetary impact, in the design of a broad regional screening dementia strategy. PMH28 INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER Liu X1, Gelwicks SC2, Faries D2, Watson PR1, Johnstone BM1 1 Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA OBJECTIVES: Our recent study showed that multiple factors including patient characteristics, comorbidities, prior medications, prior health care utilization and costs were associated with initial prescription dosage of duloxetine in the treatment of major depressive disorder (MDD). The purpose of the present study was to examine the associations between initial prescription dosage of duloxetine and hospitalization and costs in the 1-year follow-up period. METHODS: Of 10,128 patients with MDD in a large commercial administrative claims database who were initiated on duloxetine between July 1, 2005 and June 30, 2006 and had no prescriptions of duloxetine in the prior 6 months, 6132 (60.5%) had continuous enrollment for 12 months prior to and post-duloxetine initiation. According to initial prescription dose, patients were divided into 3 cohorts: low-dose ( 60 mg/day, n 1,989), mid-dose (60 mg/day, n 3,733), and high-dose ( 60 mg/day, n 410). Intent-to-treat analysis was conducted to compare health care utilization and costs in the 1 year prior and post-initiation across the 3 cohorts. RESULTS: During the post 1 year, hospitalization rate was significantly reduced by 5.7% for mid-dose cohort (p 0.001), 6.9% for high-dose cohort (p 0.05), and 7.3% for low-dose cohort (p 0.001). Pharmacy costs in the post 1 year increased in all 3 cohorts: low-dose, $672 (p 0.001); mid-dose, $825 (p 0.001); and high-dose, $1437 (p 0.05). However, mean medical costs declined in high-dose patients ($2617) and mid-dose patients ($340), but increased in low-dose patients ($261). Mean total health care costs numerically declined by $1,180 ($20,225-$21,406) in high-dose patients, but increased in low-dose patients by $933 ($18,002–$17,069) and mid-dose patients by $485 ($16,917-$16,432), although these cost changes were not significant. CONCLUSIONS: The hospitalization rate was significantly reduced in all patients after duloxetine initiation. Although pharmacy costs increased more in high-dose patients than in mid- and low-dose patients; the higher medication costs were offset by lower medical costs. PMH29 DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF DULOXETINE VERSUS OTHER ANTIDEPRESSANTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK Shi L1, Liu J1, Zhao Y2 1 Tulane University, New Orleans, LA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: This retrospective study aimed to compare health care utilization associated with duloxetine versus other antidepressants for patients with major depressive disorder (MDD) in the Veterans Affairs (VA) health system. Duloxetine was not on the VA national drug formulary. METHODS: The electronic medical records from October 2004 to October 2008 were extracted from the VA Veterans Integrated Service Network 16 data warehouse. All patients were treated with either duloxetine monotherapy or other antidepressants (non-duloxetine) over the study period. The first dispense date of the index agent was defined as the index date. All patients